NASDAQ NMS - GLOBAL MARKET · PTCT
+1.62% · +$1.15 · Vol 1.1M
Market closed · last close 4:00 PM ET · price as of 16:02:44 ET
PTC Therapeutics Inc

PTC Therapeutics Inc

Biotechnology
$72.00
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
PTCT
PTC Therapeutics Inc
Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PTCT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PTCT catalysts
About PTC Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2013
Employees
991
Country
US

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$71.71
Day high
$73.37
Day low
$70.95
Previous close
$70.85
52W high
$89.55
-19.60% from high
52W low
$43.30
62% of range
Market cap
$6.1B
P/E
8.66×
EPS
$0.2600
Beta
0.42
Shares out
83.5M
Volume
1.1M
0.61× rel vol
Avg volume
1.8M
VWAP
$72.64
Price history computed in-house
1W
+5.87%
1M
-19.60%
3M
-2.29%
1Y
+58.66%
YTD
-5.21%
SMA 50 $77.19 · below
SMA 200 $73.19 · below
52W position 62%

PTCT overview

Veridion Score
59
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PTCT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PTCT Form 4 filings
Public disclosures

Congress activity in PTCT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PTCT in the cached public ledger.

Federal contracts

PTCT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PTCT in this window.
Lobbying spend

PTCT lobbying filings, year to date.

Registered lobbying filings matched to PTC Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PTCT in this window.
Loading news for PTCT
Analyst ratings
Sovereign unlock shows live analyst consensus for PTCT.
Options
Sovereign unlock shows live options positioning for PTCT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.